RELOGABLE S.L.

Their core work

RELOGABLE S.L. is a Madrid-based technology SME that develops smart sensing and real-time monitoring systems for critical applications. Their work spans two distinct domains: power grid infrastructure (monitoring the physical state of overhead transmission lines) and medical diagnostics (a point-of-care device for patients self-managing oral anticoagulant therapy). The unifying thread across both projects is the development of compact, intelligent devices that turn a complex measurement problem into an actionable, real-time signal. Both concepts were explored under the EU SME Instrument Phase 1, meaning they pursued funded feasibility studies to validate commercial viability before committing to full product development.

What they specialise in

How they've shifted over time

RELOGABLE began in 2015 with a focus on industrial energy infrastructure, specifically monitoring high-voltage overhead lines — a problem rooted in utilities and grid operators. By 2017 they had pivoted sharply toward health technology, specifically a consumer-facing medical device for anticoagulation self-management. This is an unusually wide domain shift for a two-project SME and likely reflects either a technology platform (sensing/IoT) they believe is applicable across sectors, or a deliberate pivot driven by market feedback from the energy feasibility study. No keyword data is available to confirm the technical continuity, so this evolution should be interpreted with caution.

After shifting from energy infrastructure to health diagnostics in just two years, RELOGABLE appears to be an opportunistic innovator testing different application markets for a core sensing technology — their future direction is difficult to predict without more recent activity.

How they like to work

RELOGABLE has exclusively applied for EU funding as a solo coordinator under the SME Instrument Phase 1 scheme, which by design does not require consortium partners. As a result, they have zero recorded collaboration partners in H2020. This tells us they are comfortable leading their own technology agenda and pitching directly to the European Commission, but it gives no evidence of how they perform inside a multi-partner consortium — which would be the norm for any Phase 2 or Horizon Europe project.

RELOGABLE has no recorded consortium partners across their two H2020 projects, a direct consequence of the solo-application structure of SME Instrument Phase 1 grants. Their network in the EU research landscape, at least as captured in CORDIS, is essentially a single node.

What sets them apart

RELOGABLE is one of the rare SMEs that secured back-to-back SME Instrument Phase 1 grants in two completely different sectors — energy and health — which suggests an adaptable technology base rather than deep single-domain specialisation. For a consortium builder, this is a double-edged profile: they bring entrepreneurial drive and EU grant experience, but their actual depth in either domain is limited to feasibility-stage work with no publicly visible Phase 2 follow-through. They would be most valuable as an agile SME partner that can frame industrial or clinical problems in commercially viable terms.

Highlights from their portfolio

• CoaguPOC
  A rare cross-over into medical devices for a company that started in energy, targeting the large and regulated oral anticoagulation market with a patient self-management device.
• SMS-OHTL
  Addresses a real operational pain point for transmission system operators — real-time line state monitoring — with a smart sensor approach that has clear commercial interest from utilities.